Sprout Health Reviews: What the $199 Becomes, and the Verdict

The one-sentence version

Sprout Health sells one thing well: a single all-in NAD+ injection program with the clinician evaluation, the injection kit and expedited shipping inside one monthly figure and no minimum term. The figure is $249, not the $199 the site leads with — $199 buys the first month only — and it renews every four weeks, which is thirteen charges a year rather than twelve. It grades A, 11 points out of 14, and it is a partner here. It loses its points in one place, and it is not the price.

What Sprout Health is, and who it's for

Sprout Health is a LegitScript-certified telehealth practice operated by Sprout Health Partners LLC. Its longevity line is deliberately narrow — compounded NAD+ as a subcutaneous injection, sold as a single program rather than a menu — alongside a larger compounded GLP-1 business. You complete a medical intake, "a licensed provider will review your info and determine if NAD+ therapy is right for you — no clinic visit required," and if approved the prescription goes to a compounding pharmacy. Shipping is "free, discreet" and quoted at three to seven business days after approval.

There is no lab gate and no membership wrapper. That is genuinely the low-friction end of this category, and it suits a buyer who wants one route, one price and no diagnostic preamble. A buyer who wants baseline biomarkers before starting is in the wrong shop and should read longevity clinics versus lab memberships first.

What it actually costs, and what "$199" is doing

The headline and the real rate. The NAD+ page prices the monthly plan at "$199 / first month" then "$249 /mo after" for a 1,000 mg, 5 mL vial. The program page says it more directly: "$199 your first month, then auto renews at $249 every 4 weeks." So $199 is an introductory rate that steps up at the first refill, and $249 is what you actually pay from month two onward. To Sprout's credit, both pages state the step-up in plain language on their face — several competitors bury the equivalent in a policy document.

The four-week cadence is the part to do arithmetic on. "Every 4 weeks" is thirteen billing cycles in a year, not twelve. At $249 that is roughly $3,237 a year, about $249 more than the $2,988 that "per month" implies. No page states the annual figure.

There is a cheaper prepay tier. A three-month plan runs "$175 / first month" then "$225 /mo after" — about $24 a month less than the monthly plan, in exchange for paying up front. Unusually, leaving it is fair: the refund policy grants pro-rata refunds for unshipped months, and works the example — a $233.33-per-month plan value refunding $233.33 if you cancel after two of three shipments. That is a materially better multi-month exit than most providers here offer.

No minimum term. "No long-term contracts." Cancel whenever you like, subject to one tripwire below.

Cancel 48 hours early. "To avoid being charged for the next billing cycle, we need to receive your cancellation request at least 48 hours before your next scheduled billing date. Requests received after that window will take effect the following cycle, and the upcoming charge will still apply."

The free consult is conditional. The program page promises "free initial consultation: if you're not eligible, you pay nothing" — and that is true as written. What is also true, from the refund policy, is that once a provider has reviewed you and you change your mind before the prescription reaches the pharmacy, you get a "refund minus a flat $50 clinical review fee, reflecting the completed provider consultation." Being declined costs nothing; being approved and reconsidering costs $50. After the prescription reaches the pharmacy it is non-refundable, which is standard and lawful — dispensed medication cannot be restocked.

What's included, and what isn't

Included in $249: the clinician evaluation, the compounded NAD+ vial, "all supplies to get started right away" — syringes and alcohol wipes — and free expedited shipping. One figure, no add-ons, no membership.

Not included, and this is where the row loses points: no coaching, no dietitian time, no bundled human support beyond the care team, and no bloodwork at any stage. Nothing in the program measures whether the injections changed anything about you. For what such measurement would actually involve, see longevity biomarker panels.

Clinical oversight and the pharmacy

A licensed provider reviews every intake before anything ships, and that review is inside the price rather than billed separately — worth two of our fourteen points, and Sprout earns them.

The pharmacy is where it drops the rest — but only half of it. Sprout does name its dispensing pharmacies. Section 29 of its Terms, headed "External Services Contacts," and the same block in its HIPAA notice both list MDI (MD Integrations) as the clinician network, Foothills Pharmacy and Promise Pharmacy, each with a contact address. Two named, checkable entities, published on two documents Sprout controls.

What it will not do is classify them. On the product page it says only that its NAD+ is "compounded in the United States by state-licensed pharmacies" following "strict pharmaceutical protocols" — and the strings "503A" and "503B" appear nowhere on the site at all. When its own press material was asked the question directly, it declined to answer: "Is the pharmacy state-licensed and operating under Section 503A or 503B of the FD&C Act? This varies by pharmacy and should be confirmed directly with the dispensing entity." Naming the facility without stating its section is the middle rung of our pharmacy test, so this factor scores one of two.

The distinction is not pedantry. A 503B outsourcing facility must follow current good manufacturing practice; a 503A compounding pharmacy specifically is not subject to those requirements¹. And either way, FDA is explicit: "compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"¹.

The FDA warning letter, in proportion

On 9 September 2025, FDA issued a warning letter to Sprout Health Partners LLC dba Sprout Health (MARCS-CMS 715879). That is the entity name exactly as the letter's own recipient block writes it, and it is how you find the letter yourself: search that string in the [FDA's warning-letter database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)². The letter remains open — FDA's index records no close-out date against it.

We state that the letter exists, who it was addressed to, and when. We do not restate what it alleges, and that restraint is deliberate: summarizing an enforcement action on a page that earns a commission from the company would be us making the accusation, where naming the addressee and the date is us reporting that the FDA made one. FDA's copy is one search away and says it better than a paraphrase would.

What is worth stating, because omitting it would mislead in the other direction, is the letter's scope: it concerns the company's compounded GLP-1 line, not the NAD+ program this review is about.

What the research says, in short

Sprout sells NAD+ as energy, recovery and "age reversal." The human evidence does not carry that. NAD+ precursors do raise NAD+ levels in the blood, but no human trial shows that raising them improves energy, cognition or the rate of aging — and injected NAD+, the only route Sprout sells, has the least outcome data of all. The detail is in NAD+ for longevity, do NAD+ peptides actually work and what's proven versus hyped.

Where it's weak, and who should skip it

Skip Sprout if you want to know which pharmacy standard applies to your vial — it will not tell you, and it has said so in writing. Skip it if you want coaching, follow-up or any measurement of effect; this is a dispensing program, not a care program. Skip it if $249 every four weeks for a single injectable route looks expensive next to the ranking, because it is at the top of the month-to-month range.

If you proceed, do three things: budget $249 rather than $199, budget thirteen cycles rather than twelve, and set a reminder 48 hours before each billing date.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), whether the provider sells real longevity medicine (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Sprout takes the full four for price transparency — one all-in published figure, no membership, no prepay required to reach it, and the step-up disclosed on the page rather than buried. It takes four for a genuine longevity line and two for a clinician review inside the price. It takes one of two for pharmacy — it names Foothills and Promise in its Terms and HIPAA notice, which is the middle rung, but never says whether either is a 503A or 503B facility, which is the top one — and zero for support, because nothing beyond the care team is bundled. Eleven of fourteen. An A, at the floor of the band.

That is a fair reflection of what it is: an honest, narrow, slightly expensive program that tells you who fills the vial but not what kind of pharmacy fills it. The price is not the criticism — the criticism is that a company willing to publish a real recurring rate, a real cancellation window, a pro-rata multi-month refund and two named pharmacies is still willing to send you to the pharmacy for the one remaining answer it could give itself. Adding the section to the two names already published would take Sprout to the top rung and twelve of fourteen. The full graded field is at our provider rankings, the scoring is set out in how we grade, and two neighbors are in our Enhance MD review and Shed review.